Asuragen, Inc. and Collaborators Report Results Using PCR-Only Technologies for the Comprehensive Molecular Assessment of the Fragile X Gene

AUSTIN, Texas--(BUSINESS WIRE)--Asuragen, Inc. announced today the results from two collaborative studies, one with the University of California Davis M.I.N.D. Institute and another with Rush University Medical Center, that demonstrate comprehensive molecular profiling of the Fragile X Mental Retardation (FMR1) gene using advanced PCR-based methods. Findings from the first study, titled “An Information-Rich CGG Repeat Primed PCR That Detects the Full Range of Fragile X Expanded Alleles and Minimizes the Need for Southern Blot Analysis,” were published online by the Journal of Molecular Diagnostics and will appear in print in the September 2010 issue. The results of the second study, titled “Applications of Novel PCR Technologies that Provide Enhanced Molecular Characterization of the Fragile X Gene” were recently presented at the 12th International Fragile X Conference in Detroit, Michigan by Andrew Hadd, Ph.D., Senior Scientist at Asuragen. Both studies significantly demonstrate Asuragen’s breakthrough PCR technologies by offering sensitive, specific, and robust detection of fragile X expanded alleles, and more informative genotyping data than existing methods.

Back to news